Related references
Note: Only part of the references are listed.Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
Bryce J. B. Nelson et al.
PHARMACEUTICS (2021)
Development of alpha particle emitting radionuclide therapy according to GMP guidelines for treatment of mCRPC
Eline Hooijman et al.
NUCLEAR MEDICINE AND BIOLOGY (2021)
Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis
George Sgouros et al.
EJNMMI PHYSICS (2021)
Supply and Clinical Application of Actinium-225 and Bismuth-213
Alfred Morgenstern et al.
SEMINARS IN NUCLEAR MEDICINE (2020)
Administration of lower doses of radium-224 to ankylosing spondylitis patients results in no evidence of significant overall detriment
Nicholas D. Priest et al.
PLOS ONE (2020)
232Th-Spallation-Produced 225AC with Reduced 227AC Content
Andrew K. H. Robertson et al.
INORGANIC CHEMISTRY (2020)
Defining Processing Times for Accelerator Produced 225Ac and Other Isotopes from Proton Irradiated Thorium
Jonathan Fitzsimmons et al.
MOLECULES (2019)
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Urs B. Hagemann et al.
CLINICAL CANCER RESEARCH (2019)
In vivo Evaluation of Free and Chelated Accelerator-produced Actinium-225 - Radiation Dosimetry and Toxicity Results
Zewei Jiang et al.
CURRENT RADIOPHARMACEUTICALS (2018)
Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight
Heinz H. Coenen et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
A Radium-223 microgenerator from cyclotron-produced trace Actinium-227
Diane S. Abou et al.
APPLIED RADIATION AND ISOTOPES (2017)
Whole-Body and Microenvironmental Localization of Radium-223 in Naive and Mouse Models of Prostate Cancer Metastasis
Diane S. Abou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Whole-Body and Microenvironmental Localization of Radium-223 in Naive and Mouse Models of Prostate Cancer Metastasis
Diane S. Abou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Large scale accelerator production of 225AC: Effective cross sections for 78-192 MeV protons incident on 232Th targets
J. R. Griswold et al.
APPLIED RADIATION AND ISOTOPES (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Application of ion exchange and extraction chromatography to the separation of actinium from proton-irradiated thorium metal for analytical purposes
V. Radchenko et al.
JOURNAL OF CHROMATOGRAPHY A (2015)
Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging
Katarina Sjogreen Gleisner et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Consequences of Meta-Stable Lu-177m Admixture in Lu-177 for Patient Dosimetry
Mark W. Konijnenberg
CURRENT RADIOPHARMACEUTICALS (2015)
Radium Ra 223 Dichloride Injection: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2014)
90Sr Content in 90Y-labeled SIR-Spheres and Zevalin
John Metyko et al.
HEALTH PHYSICS (2014)
Measurement of the 225Ac half-life
S. Pomme et al.
APPLIED RADIATION AND ISOTOPES (2012)
Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200 MeV
J. W. Weidner et al.
APPLIED RADIATION AND ISOTOPES (2012)
Long-lived Impurities of 90Y-labeled Microspheres, TheraSphere and SIR-Spheres, and the Impact on Patient Dose and Waste Management
John Metyko et al.
HEALTH PHYSICS (2012)
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
Nasir Abbas et al.
NUCLEAR MEDICINE COMMUNICATIONS (2012)
Production of actinium, thorium and radium isotopes from natural thorium irradiated with protons up to 141 MeV
S. V. Ermolaev et al.
RADIOCHIMICA ACTA (2012)
Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
David A. Scheinberg et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)
Joseph G. Jurcic et al.
BLOOD (2011)
Incidence of leukaemia and other malignant diseases following injections of the short-lived α-emitter 224Ra into man
Roland R. Wick et al.
RADIATION AND ENVIRONMENTAL BIOPHYSICS (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Radium-224 Injections - Radiobiological Impact of an Abandoned Therapy for Ankylosing Spondylitis
R. Wick et al.
RADIOPROTECTION (2008)
Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226
G. Melville et al.
APPLIED RADIATION AND ISOTOPES (2007)
A theoretical model for the production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226
G. Melville et al.
APPLIED RADIATION AND ISOTOPES (2006)
Production of actinium-225 for alpha particle mediated radioimmunotherapy
RA Boll et al.
APPLIED RADIATION AND ISOTOPES (2005)
Therapy of ankylosing spondylitis with 224Ra-radium chloride:: dosimetry and risk considerations
M Lassmann et al.
RADIATION AND ENVIRONMENTAL BIOPHYSICS (2002)
Tumor therapy with targeted atomic nanogenerators
MR McDevitt et al.
SCIENCE (2001)
Share Paper
